Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Business & Regulation Drug Discovery

A Meeting of Mind Menders

GlaxoSmithKline and Alector have announced a global partnership to develop and commercialize two monoclonal antibodies: AL001 and AL101. The mAbs are designed to elevate progranulin (PGRN) – a key regulator of immune activity in the brain that has genetic links to multiple neurodegenerative disorders (1). PGRN is considered one of the most attractive targets for new immuno-neurology treatments.

Enrolment is currently underway for a phase III trial of AL001 in people at risk of frontotemporal dementia due to a PGRN gene mutation. AL001 is also being studied in trials of patients with symptomatic frontotemporal dementia with a mutation in the C9orf72 gene, as well as in patients with amyotrophic lateral sclerosis. Meanwhile, AL101 is being investigated to treat patients with more prevalent neurodegenerative diseases, including Parkinson’s and Alzheimer’s.

Subscribe to The Medicine Maker Newsletters

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].

  1. GlaxoSmithKline, “GSK and Alector announce global collaboration in immuno-neurology for two clinical stage first-in-class monoclonal antibodies for neurodegenerative diseases” (2021). Available at: https://bit.ly/3qORbeo

About the Author

Angus Stewart

Angus is Associate Editor of The Medicine Maker

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register